MacroGenics (MGNX)

MacroGenics’ research platform includes multi-specific antibody formats, including molecules it calls DART and TRIDENT, as well as antibody-drug conjugates. These technologies are designed to improve the way antibodies bind to targets, combine immune checkpoint activity, or carry cancer-killing payloads to selected cells. The company’s pipeline includes lorigerlimab, a bispecific DART molecule aimed at PD-1 and CTLA-4, two well-known immune checkpoint pathways in oncology.

The company is also advancing antibody-drug conjugate candidates such as MGC026, which targets B7-H3, and MGC028, which targets ADAM9. Both are designed to deliver a topoisomerase I inhibitor-based linker-payload to cancer cells expressing the relevant targets. These programs reflect a broader industry push toward ADCs, a drug class that has attracted strong interest from large pharmaceutical companies because of its potential to combine antibody specificity with cytotoxic potency.

MacroGenics has historically pursued both wholly owned programs and collaborations, a common strategy for biotechnology firms seeking to fund research while retaining exposure to pipeline success. For investors, the stock is primarily influenced by clinical trial results, safety data, regulatory developments, partnership activity, cash runway, and the perceived commercial opportunity for its oncology candidates.